Repligen Corp. (RGEN)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

41 SEYON STREET WALTHAM, MA 02453

Repligen Corp. develops novel therapeutics for the treatment of diseases of the central nervous system. The company markets Protein A products which are used in the production of monoclonal antibodies, and SecreFlo, used as an aid in the diagnosis of certain pancreatic disorders.

Data as of 2020-07-04
Market Cap6.625 Billion Shares Outstanding52.306 Million Avg 30-day Volume863.972 Thousand
P/E Ratio281.4 Dividend Yield EPS0.45
Price/Sales30.81 Price cash flow ratio96.3 Price free cash flow ratio204.4
Book Value20.45 Price to Tangible Book16.86 Alpha0.02
Short Interest Ratio % Short Interest to Float R-squared0.199031
BETA1.07521 52-week High/Low143.93 / 72.32 Stddev0.102633
View SEC Filings from RGEN instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 11 5 (0.33%)
13F Filers holding this stock: 304 68 (4.45%)
Aggregate 13F shares on 03/31/2020: 46.554 Million 18.591 Million
Aggregate 13F shares on 12/31/2019: 43.679 Million 16.627 Million
Percent change: 6.58% 11.81%
Funds creating new positions: 49 9
Funds Adding to an existing position: 98 25
Funds closing out their position: 42 21
Funds reducing their position: 117 28
Heat Map Ranking for 03/31/2020 343
Heat Map Ranking for 12/31/2019 35
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding RGEN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RGEN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

96.9 Thousand total shares from 38 transactions

Exercise Derivative Conversion (M)

72.3 Thousand total shares from 8 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BARTHELEMY NICOLAS

  • Director
165,242 2020-06-23 4

LIEBER JONATHAN I

  • Director
0 2020-06-19 0

DAWES KAREN A

  • Director
100,734 2020-06-18 7

EDDLEMAN ROY T

  • 10% Owner
811,835 2020-06-18 0

MUIR GLENN P

  • Director
0 2020-06-11 1

EGLINTON MANNER CARRIE

  • Director
0 2020-06-11 2

SPURR ROBERT PRESIDENT, SALIX

  • Officer
40,250 2020-05-27 0

HUNT ANTHONY CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
233,327 2020-05-21 6

SNODGRES JON CHIEF FINANCIAL OFFICER

  • Officer
32,267 2020-05-15 7

KURIYEL RALF SENIOR VP, R&D

  • Officer
26,089 2020-05-15 6

RYAN THOMAS F JR

  • Director
2,450 2020-05-13 3

COX JOHN

  • Director
923 2020-03-24 4

MHATRE ROHIN

  • Director
0 2020-03-01 2

COOPER GLENN L MD

  • Director
35,709 2019-05-23 0

BENJAMIN HOWARD VP BUSINESS DEVELOPMENT

  • Officer
33,908 2017-12-14 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

LAMPERT MARK N

  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
No longer subject to file 2017-07-14 0

RUSCHE JAMES R SENIOR VICE PRESIDENT

  • Officer
No longer subject to file 2016-12-31 0

GOLDBERG ALFRED LEWIS

  • Director
40,331 2015-05-21 0

HERLIHY WALTER C PRESIDENT, CEO

  • Officer
  • Director
262,430 2015-05-12 0

GRIFFITH MICHAEL A

  • Director
1,932 2014-11-10 0

WITT DANIEL P SENIOR VICE PRESIDENT

  • Officer
77,999 2014-06-20 0

KELLY WILLIAM J CHIEF ACCOUNTING OFFICER

  • Officer
5,456 2014-02-27 0

HENRY EARL WEBB

  • Director
21,380 2013-05-09 0

HALL MICHAEL CHIEF MEDICAL OFFICER

  • Officer
5,000 2012-03-12 0

RICH ALEXANDER

  • Director
0 2011-12-15 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

DAWES KAREN A - Director

2020-06-18 S 2,568 $116.56 d 100,734 100,734.00 direct

DAWES KAREN A - Director

2020-06-18 S 2,677 $113.58 d 116,762 100,734.00 direct

DAWES KAREN A - Director

2020-06-18 S 8,217 $115.76 d 103,302 100,734.00 direct

DAWES KAREN A - Director

2020-06-18 S 5,243 $114.49 d 111,519 100,734.00 direct

EGLINTON MANNER CARRIE - Director

2020-06-11 A 2,794 a 2,794 0.00 direct

HUNT ANTHONY - Director - Officer CHIEF EXECUTIVE OFFICER

2020-05-21 M 39,037 d 0 233,327.00 direct

HUNT ANTHONY - Director - Officer CHIEF EXECUTIVE OFFICER

2020-05-21 S 100 $141.58 d 230,241 233,327.00 direct

HUNT ANTHONY - Director - Officer CHIEF EXECUTIVE OFFICER

2020-05-21 S 16,496 $139.17 d 260,698 233,327.00 direct

HUNT ANTHONY - Director - Officer CHIEF EXECUTIVE OFFICER

2020-05-21 M 7,916 d 1 233,327.00 direct

HUNT ANTHONY - Director - Officer CHIEF EXECUTIVE OFFICER

2020-05-21 S 1,377 $140.99 d 230,341 233,327.00 direct

HUNT ANTHONY - Director - Officer CHIEF EXECUTIVE OFFICER

2020-05-21 M 39,037 $24.98 a 277,194 233,327.00 direct

HUNT ANTHONY - Director - Officer CHIEF EXECUTIVE OFFICER

2020-05-21 M 3,086 d 50,154 233,327.00 direct

HUNT ANTHONY - Director - Officer CHIEF EXECUTIVE OFFICER

2020-05-21 M 3,086 $32.40 a 233,327 233,327.00 direct

HUNT ANTHONY - Director - Officer CHIEF EXECUTIVE OFFICER

2020-05-21 S 28,980 $140.04 d 231,718 233,327.00 direct

HUNT ANTHONY - Director - Officer CHIEF EXECUTIVE OFFICER

2020-05-21 M 7,916 $16.55 a 238,157 233,327.00 direct

DAWES KAREN A - Director

2020-05-20 S 182 $140.29 d 119,439 119,439.00 direct

DAWES KAREN A - Director

2020-05-20 S 10 $135.91 d 119,946 119,439.00 direct

DAWES KAREN A - Director

2020-05-20 S 282 $139.40 d 119,621 119,439.00 direct

DAWES KAREN A - Director

2020-05-20 S 43 $136.98 d 119,903 119,439.00 direct

DAWES KAREN A - Director

2020-05-18 S 80 $142.45 d 119,956 119,956.00 direct

DAWES KAREN A - Director

2020-05-18 S 122 $139.32 d 120,293 119,956.00 direct

DAWES KAREN A - Director

2020-05-18 S 712 $135.76 d 120,844 119,956.00 direct

BARTHELEMY NICOLAS - Director

2020-05-18 M 2,109 a 0 2,664.00 direct

DAWES KAREN A - Director

2020-05-18 S 77 $141.45 d 120,036 119,956.00 direct

DAWES KAREN A - Director

2020-05-18 S 269 $138.60 d 120,415 119,956.00 direct

DAWES KAREN A - Director

2020-05-18 S 77 $141.45 d 120,036 119,956.00 direct

DAWES KAREN A - Director

2020-05-18 S 269 $138.60 d 120,415 119,956.00 direct

BARTHELEMY NICOLAS - Director

2020-05-18 S 3,009 $142.53 d 2,664 2,664.00 direct

DAWES KAREN A - Director

2020-05-18 S 180 $140.62 d 120,113 119,956.00 direct

DAWES KAREN A - Director

2020-05-18 S 160 $136.92 d 120,684 119,956.00 direct

DAWES KAREN A - Director

2020-05-18 S 180 $140.62 d 120,113 119,956.00 direct

DAWES KAREN A - Director

2020-05-18 S 160 $136.92 d 120,684 119,956.00 direct

BARTHELEMY NICOLAS - Director

2020-05-18 M 2,109 $67.71 a 5,673 2,664.00 direct

DAWES KAREN A - Director

2020-05-18 S 80 $142.45 d 119,956 119,956.00 direct

DAWES KAREN A - Director

2020-05-18 S 122 $139.32 d 120,293 119,956.00 direct

DAWES KAREN A - Director

2020-05-18 S 712 $135.76 d 120,844 119,956.00 direct

KURIYEL RALF - Officer SENIOR VP, R&D

2020-05-15 S 435 $140.69 d 26,089 26,089.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2020-05-15 S 660 $140.43 d 32,267 32,267.00 direct

MUIR GLENN P - Director

2020-05-13 A 527 a 5,905 5,905.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2020-05-13 M 3,170 $26.05 a 39,297 32,927.00 direct

RYAN THOMAS F JR - Director

2020-05-13 A 1,285 a 1,285 2,450.00 direct

KURIYEL RALF - Officer SENIOR VP, R&D

2020-05-13 S 95 $128.55 d 26,524 26,524.00 direct

KURIYEL RALF - Officer SENIOR VP, R&D

2020-05-13 M 2,000 $33.87 a 34,524 26,524.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2020-05-13 M 3,170 d 0 32,927.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2020-05-13 S 1,700 $130.20 d 36,786 32,927.00 direct

DAWES KAREN A - Director

2020-05-13 A 722 a 121,556 119,956.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2020-05-13 S 5,358 $126.77 d 42,963 32,927.00 direct

BARTHELEMY NICOLAS - Director

2020-05-13 A 1,285 a 1,285 3,564.00 direct

RYAN THOMAS F JR - Director

2020-05-13 A 527 a 2,450 2,450.00 direct

DAWES KAREN A - Director

2020-05-13 A 722 a 121,556 119,956.00 direct

KURIYEL RALF - Officer SENIOR VP, R&D

2020-05-13 M 2,000 d 10,850 26,524.00 direct

KURIYEL RALF - Officer SENIOR VP, R&D

2020-05-13 S 6,293 $128.02 d 26,619 26,524.00 direct

KURIYEL RALF - Officer SENIOR VP, R&D

2020-05-13 M 6,000 $33.05 a 32,524 26,524.00 direct

DAWES KAREN A - Director

2020-05-13 A 1,761 a 1,761 119,956.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2020-05-13 S 846 $132.37 d 32,927 32,927.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2020-05-13 S 1,612 $128.70 d 38,486 32,927.00 direct

MUIR GLENN P - Director

2020-05-13 A 1,285 a 1,285 5,905.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2020-05-13 M 9,024 $32.40 a 48,321 32,927.00 direct

BARTHELEMY NICOLAS - Director

2020-05-13 A 527 a 3,564 3,564.00 direct

DAWES KAREN A - Director

2020-05-13 A 1,761 a 1,761 119,956.00 direct

KURIYEL RALF - Officer SENIOR VP, R&D

2020-05-13 M 6,000 d 4,000 26,524.00 direct

KURIYEL RALF - Officer SENIOR VP, R&D

2020-05-13 S 1,612 $126.88 d 32,912 26,524.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2020-05-13 M 9,024 d 3,086 32,927.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2020-05-13 S 3,013 $131.38 d 33,773 32,927.00 direct

SNODGRES JON - Officer CHIEF FINANCIAL OFFICER

2020-05-13 S 2,865 $127.75 d 40,098 32,927.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments